Merck’s exceptional revenue growth in 2021 and the first half of 2022 came thanks to three big brands, one of which is not even approved by the FDA yet.
https://www.pharmalive.com/wp-content/uploads/2018/10/Keytruda.jpg24913013Joshua Slatkohttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngJoshua Slatko2022-10-11 02:20:282022-10-04 11:43:36Merck 2022: The three towers
